FDA — authorised 2 August 2022
- Application: BLA761165
- Marketing authorisation holder: SANDOZ INC
- Local brand name: CIMERLI
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 CIMERLI in United States
FDA authorised CIMERLI on 2 August 2022
Marketing authorisation
CIMERLI in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is CIMERLI approved in United States?
Yes. FDA authorised it on 2 August 2022.
Who is the marketing authorisation holder for CIMERLI in United States?
SANDOZ INC holds the US marketing authorisation.